Skip to main content
NCBI home page
Quality in Health Care : QHC logoLink to Quality in Health Care : QHC
. 1998 Sep;7(3):170–177. doi: 10.1136/qshc.7.3.170

Management of lung cancer

A Melville, A Eastwood
PMCID: PMC2483609  PMID: 10185145

Full Text

The Full Text of this article is available as a PDF (136.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addington-Hall J., McCarthy M. Dying from cancer: results of a national population-based investigation. Palliat Med. 1995 Oct;9(4):295–305. doi: 10.1177/026921639500900404. [DOI] [PubMed] [Google Scholar]
  2. Arriagada R., Le Chevalier T., Borie F., Rivière A., Chomy P., Monnet I., Tardivon A., Viader F., Tarayre M., Benhamou S. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995 Feb 1;87(3):183–190. doi: 10.1093/jnci/87.3.183. [DOI] [PubMed] [Google Scholar]
  3. Aygun C., Weiner S., Scariato A., Spearman D., Stark L. Treatment of non-small cell lung cancer with external beam radiotherapy and high dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1992;23(1):127–132. doi: 10.1016/0360-3016(92)90551-r. [DOI] [PubMed] [Google Scholar]
  4. Bakker W., van Oosterom A. T., Aaronson N. K., van Breukelen F. J., Bins M. C., Hermans J. Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol. 1986 Aug;22(8):963–970. doi: 10.1016/0277-5379(86)90063-5. [DOI] [PubMed] [Google Scholar]
  5. Bedwinek J., Petty A., Bruton C., Sofield J., Lee L. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 1992;22(1):23–30. doi: 10.1016/0360-3016(92)90978-q. [DOI] [PubMed] [Google Scholar]
  6. Begg C. B., Cohen J. L., Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials. 1980;3(4):369–374. [PubMed] [Google Scholar]
  7. Bonnefoi H., Smith I. E. How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer. 1996 Sep;74(5):832–835. doi: 10.1038/bjc.1996.444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bruera E., Macmillan K., Pither J., MacDonald R. N. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage. 1990 Dec;5(6):341–344. doi: 10.1016/0885-3924(90)90027-h. [DOI] [PubMed] [Google Scholar]
  9. Brundage M. D., Davidson J. R., Mackillop W. J. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997 Jan;15(1):330–340. doi: 10.1200/JCO.1997.15.1.330. [DOI] [PubMed] [Google Scholar]
  10. Bunn P. A., Jr, Carney D. N. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7–69-S7-74. [PubMed] [Google Scholar]
  11. Chang L. F., Horvath J., Peyton W., Ling S. S. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):589–596. doi: 10.1016/0360-3016(94)90183-x. [DOI] [PubMed] [Google Scholar]
  12. Collins T. M., Ash D. V., Close H. J., Thorogood J. An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchus. Clin Radiol. 1988 May;39(3):284–286. doi: 10.1016/s0009-9260(88)80536-1. [DOI] [PubMed] [Google Scholar]
  13. Comella P., Frasci G., De Cataldis G., Panza N., Cioffi R., Curcio C., Belli M., Bianco A., Ianniello G., Maiorino L. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer. 1996 Dec;74(11):1805–1811. doi: 10.1038/bjc.1996.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Corner J., Plant H., A'Hern R., Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med. 1996 Oct;10(4):299–305. doi: 10.1177/026921639601000405. [DOI] [PubMed] [Google Scholar]
  15. Coultas D. B., Samet J. M. Occupational lung cancer. Clin Chest Med. 1992 Jun;13(2):341–354. [PubMed] [Google Scholar]
  16. Coyle D., Drummond M. F. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Medical Research Council CHART Steering Committee. Clin Oncol (R Coll Radiol) 1997;9(5):313–321. doi: 10.1016/s0936-6555(05)80065-2. [DOI] [PubMed] [Google Scholar]
  17. Cromwell J., Bartosch W. J., Fiore M. C., Hasselblad V., Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997 Dec 3;278(21):1759–1766. [PubMed] [Google Scholar]
  18. Cullen M. H. Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Lung Cancer. 1995 Apr;12 (Suppl 1):S95–106. doi: 10.1016/0169-5002(95)00425-z. [DOI] [PubMed] [Google Scholar]
  19. Dales R. E., Bélanger R., Shamji F. M., Leech J., Crépeau A., Sachs H. J. Quality-of-life following thoracotomy for lung cancer. J Clin Epidemiol. 1994 Dec;47(12):1443–1449. doi: 10.1016/0895-4356(94)90088-4. [DOI] [PubMed] [Google Scholar]
  20. Darby S., Whitley E., Silcocks P., Thakrar B., Green M., Lomas P., Miles J., Reeves G., Fearn T., Doll R. Risk of lung cancer associated with residential radon exposure in south-west England: a case-control study. Br J Cancer. 1998 Aug;78(3):394–408. doi: 10.1038/bjc.1998.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Devine E. C., Westlake S. K. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Oncol Nurs Forum. 1995 Oct;22(9):1369–1381. [PubMed] [Google Scholar]
  22. Dillman R. O., Seagren S. L., Propert K. J., Guerra J., Eaton W. L., Perry M. C., Carey R. W., Frei E. F., 3rd, Green M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940–945. doi: 10.1056/NEJM199010043231403. [DOI] [PubMed] [Google Scholar]
  23. Doll R., Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981 Jun;66(6):1191–1308. [PubMed] [Google Scholar]
  24. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994 Oct 8;309(6959):901–911. doi: 10.1136/bmj.309.6959.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ellis P. A., Smith I. E., Hardy J. R., Nicolson M. C., Talbot D. C., Ashley S. E., Priest K. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995 Feb;71(2):366–370. doi: 10.1038/bjc.1995.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Escalante C. P., Martin C. G., Elting L. S., Cantor S. B., Harle T. S., Price K. J., Kish S. K., Manzullo E. F., Rubenstein E. B. Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care world. Cancer. 1996 Sep 15;78(6):1314–1319. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1314::AID-CNCR21>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  27. Evans W. K., Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer. 1996 Dec;32A(13):2249–2255. doi: 10.1016/s0959-8049(96)00298-5. [DOI] [PubMed] [Google Scholar]
  28. Evans W. K., Will B. P., Berthelot J. M., Earle C. C. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol. 1997 Sep;15(9):3038–3048. doi: 10.1200/JCO.1997.15.9.3038. [DOI] [PubMed] [Google Scholar]
  29. Evans W. K., Will B. P., Berthelot J. M., Wolfson M. C. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol. 1995 Dec;5(4):408–419. [PubMed] [Google Scholar]
  30. Evans W. K., Will B. P., Berthelot J. M., Wolfson M. C. The economics of lung cancer management in Canada. Lung Cancer. 1996 Feb;14(1):19–29. doi: 10.1016/0169-5002(95)00510-2. [DOI] [PubMed] [Google Scholar]
  31. Fakhoury W., McCarthy M., Addington-Hall J. Determinants of informal caregivers' satisfaction with services for dying cancer patients. Soc Sci Med. 1996 Mar;42(5):721–731. doi: 10.1016/0277-9536(95)00198-0. [DOI] [PubMed] [Google Scholar]
  32. Fergusson R. J., Gregor A., Dodds R., Kerr G. Management of lung cancer in South East Scotland. Thorax. 1996 Jun;51(6):569–574. doi: 10.1136/thx.51.6.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Fernandez C., Rosell R., Abad-Esteve A., Monras P., Moreno I., Serichol M., Roviralta M. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol. 1989;28(1):29–33. doi: 10.3109/02841868909111177. [DOI] [PubMed] [Google Scholar]
  34. Filshie J., Penn K., Ashley S., Davis C. L. Acupuncture for the relief of cancer-related breathlessness. Palliat Med. 1996 Apr;10(2):145–150. doi: 10.1177/026921639601000209. [DOI] [PubMed] [Google Scholar]
  35. Flagg E. W., Coates R. J., Greenberg R. S. Epidemiologic studies of antioxidants and cancer in humans. J Am Coll Nutr. 1995 Oct;14(5):419–427. doi: 10.1080/07315724.1995.10718532. [DOI] [PubMed] [Google Scholar]
  36. Flehinger B. J., Kimmel M., Melamed M. R. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest. 1992 Apr;101(4):1013–1018. doi: 10.1378/chest.101.4.1013. [DOI] [PubMed] [Google Scholar]
  37. Fulkerson W. J. Current concepts. Fiberoptic bronchoscopy. N Engl J Med. 1984 Aug 23;311(8):511–515. doi: 10.1056/NEJM198408233110806. [DOI] [PubMed] [Google Scholar]
  38. Geddes D. M., Dones L., Hill E., Law K., Harper P. G., Spiro S. G., Tobias J. S., Souhami R. L. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer. 1990 Apr;26(4):484–492. doi: 10.1016/0277-5379(90)90022-l. [DOI] [PubMed] [Google Scholar]
  39. Ginsberg R. J., Rubinstein L. V. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615–623. doi: 10.1016/0003-4975(95)00537-u. [DOI] [PubMed] [Google Scholar]
  40. Goddard M. The role of economics in the evaluation of hospice care. Health Policy. 1989 Oct;13(1):19–34. doi: 10.1016/0168-8510(89)90108-5. [DOI] [PubMed] [Google Scholar]
  41. Goldstraw P. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax. 1992 Jan;47(1):1–2. doi: 10.1136/thx.47.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Gollins S. W., Ryder W. D., Burt P. A., Barber P. V., Stout R. Massive haemoptysis death and other morbidity associated with high dose rate intraluminal radiotherapy for carcinoma of the bronchus. Radiother Oncol. 1996 May;39(2):105–116. doi: 10.1016/0167-8140(96)01731-8. [DOI] [PubMed] [Google Scholar]
  43. Goodwin P. J., Feld R., Evans W. K., Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988 Oct;6(10):1537–1547. doi: 10.1200/JCO.1988.6.10.1537. [DOI] [PubMed] [Google Scholar]
  44. Gower N. H., Rudd R. M., Ruiz de Elvira M. C., Spiro S. G., James L. E., Harper P. G., Souhami R. L. Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol. 1995 Jul;6(6):575–580. doi: 10.1093/oxfordjournals.annonc.a059247. [DOI] [PubMed] [Google Scholar]
  45. Gregor A., Cull A., Stephens R. J., Kirkpatrick J. A., Yarnold J. R., Girling D. J., Macbeth F. R., Stout R., Machin D. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC) Eur J Cancer. 1997 Oct;33(11):1752–1758. doi: 10.1016/s0959-8049(97)00135-4. [DOI] [PubMed] [Google Scholar]
  46. Grond S., Zech D., Diefenbach C., Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994 Aug;9(6):372–382. doi: 10.1016/0885-3924(94)90174-0. [DOI] [PubMed] [Google Scholar]
  47. Grunberg S. M., Boutin N., Ireland A., Miner S., Silveira J., Ashikaga T. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 1996 Nov;4(6):435–439. doi: 10.1007/BF01880641. [DOI] [PubMed] [Google Scholar]
  48. Hartman D. L., Gaither J. M., Kesler K. A., Mylet D. M., Brown J. W., Mathur P. N. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg. 1993 Apr;105(4):743–748. [PubMed] [Google Scholar]
  49. Higginson I. J., Hearn J. A multicenter evaluation of cancer pain control by palliative care teams. J Pain Symptom Manage. 1997 Jul;14(1):29–35. doi: 10.1016/S0885-3924(97)00006-7. [DOI] [PubMed] [Google Scholar]
  50. Higginson I., McCarthy M. Measuring symptoms in terminal cancer: are pain and dyspnoea controlled? J R Soc Med. 1989 May;82(5):264–267. doi: 10.1177/014107688908200507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Higginson I. Palliative care: a review of past changes and future trends. J Public Health Med. 1993 Mar;15(1):3–8. doi: 10.1093/oxfordjournals.pubmed.a042817. [DOI] [PubMed] [Google Scholar]
  52. Hinton J. Can home care maintain an acceptable quality of life for patients with terminal cancer and their relatives? Palliat Med. 1994;8(3):183–196. doi: 10.1177/026921639400800302. [DOI] [PubMed] [Google Scholar]
  53. Hollen P. J., Gralla R. J., Cox C., Eberly S. W., Kris M. G. A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer. 1997 Oct;18(2):119–136. doi: 10.1016/s0169-5002(97)00059-7. [DOI] [PubMed] [Google Scholar]
  54. Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin Oncol. 1996 Oct;23(5 Suppl 10):60–64. [PubMed] [Google Scholar]
  55. Hopwood P., Stephens R. J. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer. 1995 Mar;71(3):633–636. doi: 10.1038/bjc.1995.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Huber R. M., Fischer R., Haŭtmann H., Pöllinger B., Wendt T., Müller-Wening D., Häussinger K. Palliative endobronchial brachytherapy for central lung tumors. A prospective, randomized comparison of two fractionation schedules. Chest. 1995 Feb;107(2):463–470. doi: 10.1378/chest.107.2.463. [DOI] [PubMed] [Google Scholar]
  57. Hürny C., Bernhard J., Joss R., Schatzmann E., Cavalli F., Brunner K., Alberto P., Senn H. J., Metzger U. "Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK) Support Care Cancer. 1993 Nov;1(6):316–320. doi: 10.1007/BF00364969. [DOI] [PubMed] [Google Scholar]
  58. Jaakkimainen L., Goodwin P. J., Pater J., Warde P., Murray N., Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol. 1990 Aug;8(8):1301–1309. doi: 10.1200/JCO.1990.8.8.1301. [DOI] [PubMed] [Google Scholar]
  59. Jantunen I. T., Kataja V. V., Muhonen T. T. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997 Jan;33(1):66–74. doi: 10.1016/s0959-8049(96)00276-6. [DOI] [PubMed] [Google Scholar]
  60. Joss R. A., Alberto P., Hürny C., Bacchi M., Leyvraz S., Thürlimann B., Cerny T., Martinelli G., Stahel R., Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1995 Jan;6(1):41–48. doi: 10.1093/oxfordjournals.annonc.a059039. [DOI] [PubMed] [Google Scholar]
  61. Khanavkar B., Stern P., Alberti W., Nakhosteen J. A. Complications associated with brachytherapy alone or with laser in lung cancer. Chest. 1991 May;99(5):1062–1065. doi: 10.1378/chest.99.5.1062. [DOI] [PubMed] [Google Scholar]
  62. Klasa R. J., Murray N., Coldman A. J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991 Mar;9(3):499–508. doi: 10.1200/JCO.1991.9.3.499. [DOI] [PubMed] [Google Scholar]
  63. Lederle F. A., Niewoehner D. E. Lung cancer surgery. A critical review of the evidence. Arch Intern Med. 1994 Nov 14;154(21):2397–2400. doi: 10.1001/archinte.154.21.2397. [DOI] [PubMed] [Google Scholar]
  64. Little A. G., Ferguson M. K., Golomb H. M., Hoffman P. C., Vogelzang N. J., Skinner D. B. Pleuroperitoneal shunting for malignant pleural effusions. Cancer. 1986 Dec 15;58(12):2740–2743. doi: 10.1002/1097-0142(19861215)58:12<2740::aid-cncr2820581231>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  65. Lubin J. H., Boice J. D., Jr Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst. 1997 Jan 1;89(1):49–57. doi: 10.1093/jnci/89.1.49. [DOI] [PubMed] [Google Scholar]
  66. Macha H. N., Wahlers B., Reichle C., von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years' experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients. Lung. 1995;173(5):271–280. doi: 10.1007/BF00176890. [DOI] [PubMed] [Google Scholar]
  67. Manegold C., Bergman B., Chemaissani A., Dornoff W., Drings P., Kellokumpu-Lehtinen P., Liippo K., Mattson K., van Pawel J., Ricci S. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 1997 Jun;8(6):525–529. doi: 10.1023/a:1008207731111. [DOI] [PubMed] [Google Scholar]
  68. McCorkle R., Benoliel J. Q., Donaldson G., Georgiadou F., Moinpour C., Goodell B. A randomized clinical trial of home nursing care for lung cancer patients. Cancer. 1989 Sep 15;64(6):1375–1382. doi: 10.1002/1097-0142(19890915)64:6<1375::aid-cncr2820640634>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  69. McQuay H. J., Carroll D., Moore R. A. Radiotherapy for painful bone metastases: a systematic review. Clin Oncol (R Coll Radiol) 1997;9(3):150–154. doi: 10.1016/s0936-6555(97)80070-2. [DOI] [PubMed] [Google Scholar]
  70. Mehta A. C., Marty J. J., Lee F. Y. Sputum cytology. Clin Chest Med. 1993 Mar;14(1):69–85. [PubMed] [Google Scholar]
  71. Meredith C., Symonds P., Webster L., Lamont D., Pyper E., Gillis C. R., Fallowfield L. Information needs of cancer patients in west Scotland: cross sectional survey of patients' views. BMJ. 1996 Sep 21;313(7059):724–726. doi: 10.1136/bmj.313.7059.724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Mills M., Davies H. T., Macrae W. A. Care of dying patients in hospital. BMJ. 1994 Sep 3;309(6954):583–586. doi: 10.1136/bmj.309.6954.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Milroy R., Macbeth F. Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer. Thorax. 1995 Sep;50 (Suppl 1):S25–S30. doi: 10.1136/thx.50.suppl_1.s25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Morittu L., Earl H. M., Souhami R. L., Ash C. M., Tobias J. S., Geddes D. M., Harper P. G., Spiro S. G. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer. 1989 May;59(5):801–804. doi: 10.1038/bjc.1989.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Muers M. F., Round C. E. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993 Apr;48(4):339–343. doi: 10.1136/thx.48.4.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Nesbitt J. C., Putnam J. B., Jr, Walsh G. L., Roth J. A., Mountain C. F. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995 Aug;60(2):466–472. doi: 10.1016/0003-4975(95)00169-l. [DOI] [PubMed] [Google Scholar]
  77. Omenn G. S., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Glass A., Keogh J. P., Meyskens F. L., Jr, Valanis B., Williams J. H., Jr Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996 Nov 6;88(21):1550–1559. doi: 10.1093/jnci/88.21.1550. [DOI] [PubMed] [Google Scholar]
  78. Ornadel D., Duchesne G., Wall P., Ng A., Hetzel M. Defining the roles of high dose rate endobronchial brachytherapy and laser resection for recurrent bronchial malignancy. Lung Cancer. 1997 Mar;16(2-3):203–213. doi: 10.1016/s0169-5002(96)00630-7. [DOI] [PubMed] [Google Scholar]
  79. Osoba D., Rusthoven J. J., Turnbull K. A., Evans W. K., Shepherd F. A. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1478–1485. doi: 10.1200/JCO.1985.3.11.1478. [DOI] [PubMed] [Google Scholar]
  80. Parkes C. M. Terminal care: evaluation of in-patient service at St Christopher's Hospice. Part I. Views of surviving spouse on effects of the service on the patient. Postgrad Med J. 1979 Sep;55(646):517–522. doi: 10.1136/pgmj.55.646.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Parkes C. M. Terminal care: evaluation of in-patient service at St Christopher's Hospice. Part II. Self assessments of effects of the service on surviving spouses. Postgrad Med J. 1979 Sep;55(646):523–527. doi: 10.1136/pgmj.55.646.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Pater J. L., Zee B., Palmer M., Johnston D., Osoba D. Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30. Support Care Cancer. 1997 Sep;5(5):410–413. doi: 10.1007/s005200050100. [DOI] [PubMed] [Google Scholar]
  83. Pershagen G., Akerblom G., Axelson O., Clavensjö B., Damber L., Desai G., Enflo A., Lagarde F., Mellander H., Svartengren M. Residential radon exposure and lung cancer in Sweden. N Engl J Med. 1994 Jan 20;330(3):159–164. doi: 10.1056/NEJM199401203300302. [DOI] [PubMed] [Google Scholar]
  84. Peto J., Hodgson J. T., Matthews F. E., Jones J. R. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995 Mar 4;345(8949):535–539. doi: 10.1016/s0140-6736(95)90462-x. [DOI] [PubMed] [Google Scholar]
  85. Petrou M., Kaplan D., Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting. Cancer. 1995 Feb 1;75(3):801–805. doi: 10.1002/1097-0142(19950201)75:3<801::aid-cncr2820750309>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  86. Pignon J. P., Arriagada R., Ihde D. C., Johnson D. H., Perry M. C., Souhami R. L., Brodin O., Joss R. A., Kies M. S., Lebeau B. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 Dec 3;327(23):1618–1624. doi: 10.1056/NEJM199212033272302. [DOI] [PubMed] [Google Scholar]
  87. Pisch J., Villamena P. C., Harvey J. C., Rosenblatt E., Mishra S., Beattie E. J. High dose-rate endobronchial irradiation in malignant airway obstruction. Chest. 1993 Sep;104(3):721–725. doi: 10.1378/chest.104.3.721. [DOI] [PubMed] [Google Scholar]
  88. Ponn R. B., Blancaflor J., D'Agostino R. S., Kiernan M. E., Toole A. L., Stern H. Pleuroperitoneal shunting for intractable pleural effusions. Ann Thorac Surg. 1991 Apr;51(4):605–609. doi: 10.1016/0003-4975(91)90319-l. [DOI] [PubMed] [Google Scholar]
  89. Poroch D. The effect of preparatory patient education on the anxiety and satisfaction of cancer patients receiving radiation therapy. Cancer Nurs. 1995 Jun;18(3):206–214. [PubMed] [Google Scholar]
  90. Portenoy R. K., Thaler H. T., Kornblith A. B., Lepore J. M., Friedlander-Klar H., Coyle N., Smart-Curley T., Kemeny N., Norton L., Hoskins W. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994 Jun;3(3):183–189. doi: 10.1007/BF00435383. [DOI] [PubMed] [Google Scholar]
  91. Pérez Ciordia I., Castanera Moros A., Ferrero Cáncer M. Tuberculosis en Huesca. Aplicación del método captura-recaptura. Rev Esp Salud Publica. 1999 May-Jun;73(3):403–406. [PubMed] [Google Scholar]
  92. Raftery J. P., Addington-Hall J. M., MacDonald L. D., Anderson H. R., Bland J. M., Chamberlain J., Freeling P. A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med. 1996 Apr;10(2):151–161. doi: 10.1177/026921639601000210. [DOI] [PubMed] [Google Scholar]
  93. Rainey L. C. Effects of preparatory patient education for radiation oncology patients. Cancer. 1985 Sep 1;56(5):1056–1061. doi: 10.1002/1097-0142(19850901)56:5<1056::aid-cncr2820560516>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  94. Ream E., Richardson A. The role of information in patients' adaptation to chemotherapy and radiotherapy: a review of the literature. Eur J Cancer Care (Engl) 1996 Sep;5(3):132–138. doi: 10.1111/j.1365-2354.1996.tb00223.x. [DOI] [PubMed] [Google Scholar]
  95. Reshad K., Inui K., Takeuchi Y., Takahashi Y., Hitomi S. Treatment of malignant pleural effusion. Chest. 1985 Sep;88(3):393–397. doi: 10.1378/chest.88.3.393. [DOI] [PubMed] [Google Scholar]
  96. Reynolds P. M., Sanson-Fisher R. W., Poole A. D., Harker J., Byrne M. J. Cancer and communication: information-giving in an oncology clinic. Br Med J (Clin Res Ed) 1981 May 2;282(6274):1449–1451. doi: 10.1136/bmj.282.6274.1449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Richelme H., Bereder J. M., Mouroux J., Bernard J. L., Benchimol D. La chirurgie d'exérèse du cancer bronchique après 70 ans est-elle légitime? Chirurgie. 1990;116(4-5):385–394. [PubMed] [Google Scholar]
  98. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J. L., Li S., Roig J., Olazábal A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153–158. doi: 10.1056/NEJM199401203300301. [DOI] [PubMed] [Google Scholar]
  99. Rosso R., Rimoldi R., Salvati F., De Palma M., Cinquegrana A., Nicolò G., Ardizzoni A., Fusco U., Capaccio A., Centofanti R. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology. 1988;45(3):253–256. doi: 10.1159/000226571. [DOI] [PubMed] [Google Scholar]
  100. Roth J. A., Fossella F., Komaki R., Ryan M. B., Putnam J. B., Jr, Lee J. S., Dhingra H., De Caro L., Chasen M., McGavran M. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 4;86(9):673–680. doi: 10.1093/jnci/86.9.673. [DOI] [PubMed] [Google Scholar]
  101. Saijo N. Chemotherapy: the more the better? Overview. Cancer Chemother Pharmacol. 1997;40 (Suppl):S100–S106. doi: 10.1007/s002800051070. [DOI] [PubMed] [Google Scholar]
  102. Saunders M. I., Dische S., Barrett A., Parmar M. K., Harvey A., Gibson D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer. 1996 Jun;73(12):1455–1462. doi: 10.1038/bjc.1996.276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997 Jul 19;350(9072):161–165. doi: 10.1016/s0140-6736(97)06305-8. [DOI] [PubMed] [Google Scholar]
  104. Sculier J. P., Klastersky J., Libert P., Ravez P., Thiriaux J., Lecomte J., Bureau G., Vandermoten G., Dabouis G., Michel J. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party. Ann Oncol. 1990;1(2):128–133. doi: 10.1093/oxfordjournals.annonc.a057690. [DOI] [PubMed] [Google Scholar]
  105. Seale C. F. What happens in hospices: a review of research evidence. Soc Sci Med. 1989;28(6):551–559. doi: 10.1016/0277-9536(89)90249-9. [DOI] [PubMed] [Google Scholar]
  106. Sell L., Devlin B., Bourke S. J., Munro N. C., Corris P. A., Gibson G. J. Communicating the diagnosis of lung cancer. Respir Med. 1993 Jan;87(1):61–63. doi: 10.1016/s0954-6111(05)80315-4. [DOI] [PubMed] [Google Scholar]
  107. Shields T. W., Higgins G. A., Jr, Lawton R., Heilbrunn A., Keehn R. J. Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1970 Jan;59(1):49–61. [PubMed] [Google Scholar]
  108. Silvestri G. A., Littenberg B., Colice G. L. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med. 1995 Jul;152(1):225–230. doi: 10.1164/ajrccm.152.1.7599828. [DOI] [PubMed] [Google Scholar]
  109. Souhami R. L., Spiro S. G., Rudd R. M., Ruiz de Elvira M. C., James L. E., Gower N. H., Lamont A., Harper P. G. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997 Apr 16;89(8):577–580. doi: 10.1093/jnci/89.8.577. [DOI] [PubMed] [Google Scholar]
  110. Speiser B. L., Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):579–587. doi: 10.1016/0360-3016(93)90002-d. [DOI] [PubMed] [Google Scholar]
  111. Spiro S. G., Souhami R. L. Duration of chemotherapy in small cell lung cancer. Thorax. 1990 Jan;45(1):1–2. doi: 10.1136/thx.45.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Stephens R. J., Girling D. J., Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer. 1994 Sep;11(3-4):259–274. doi: 10.1016/0169-5002(94)90546-0. [DOI] [PubMed] [Google Scholar]
  113. Stephens R. J., Hopwood P., Girling D. J., Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res. 1997 Apr;6(3):225–236. doi: 10.1023/a:1026458604826. [DOI] [PubMed] [Google Scholar]
  114. Stevens G., Firth I. Non small cell carcinoma of the lung. A retrospective study. Presented at the 41st annual meeting of the Royal Australasian College of Radiologists, September 1990, Perth. Australas Radiol. 1992 Aug;36(3):243–248. doi: 10.1111/j.1440-1673.1992.tb03160.x. [DOI] [PubMed] [Google Scholar]
  115. Stone P., Kurowska A., Tookman A. Nebulized frusemide for dyspnoea. Palliat Med. 1994;8(3):258–258. doi: 10.1177/026921639400800315. [DOI] [PubMed] [Google Scholar]
  116. Strauss G. M., Gleason R. E., Sugarbaker D. J. Screening for lung cancer. Another look; a different view. Chest. 1997 Mar;111(3):754–768. doi: 10.1378/chest.111.3.754. [DOI] [PubMed] [Google Scholar]
  117. Tattersall M. H., Butow P. N., Griffin A. M., Dunn S. M. The take-home message: patients prefer consultation audiotapes to summary letters. J Clin Oncol. 1994 Jun;12(6):1305–1311. doi: 10.1200/JCO.1994.12.6.1305. [DOI] [PubMed] [Google Scholar]
  118. Tengs T. O., Adams M. E., Pliskin J. S., Safran D. G., Siegel J. E., Weinstein M. C., Graham J. D. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995 Jun;15(3):369–390. doi: 10.1111/j.1539-6924.1995.tb00330.x. [DOI] [PubMed] [Google Scholar]
  119. Townsend J., Frank A. O., Fermont D., Dyer S., Karran O., Walgrove A., Piper M. Terminal cancer care and patients' preference for place of death: a prospective study. BMJ. 1990 Sep 1;301(6749):415–417. doi: 10.1136/bmj.301.6749.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Tsang G. M., Watson D. C. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax. 1992 Jan;47(1):3–5. doi: 10.1136/thx.47.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Tsang V., Fernando H. C., Goldstraw P. Pleuroperitoneal shunt for recurrent malignant pleural effusions. Thorax. 1990 May;45(5):369–372. doi: 10.1136/thx.45.5.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Tummarello D., Graziano F., Isidori P., Cellerino R. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol. 1995;35(3):249–253. doi: 10.1007/BF00686556. [DOI] [PubMed] [Google Scholar]
  123. Villanueva A. G., Gray A. W., Jr, Shahian D. M., Williamson W. A., Beamis J. F., Jr Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax. 1994 Jan;49(1):23–25. doi: 10.1136/thx.49.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Vinante O., Bari M., Segati R., Azzarello G., Sampognaro E., Rosetti F., Pappagallo G. L. The combination of mitomycin, vinblastine and cisplatin is active in the palliation of stage IIIB-IV non-small-cell lung cancer. Oncology. 1993;50(1):1–4. doi: 10.1159/000227137. [DOI] [PubMed] [Google Scholar]
  125. Waller D. A., Morritt G. N., Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest. 1995 May;107(5):1454–1456. doi: 10.1378/chest.107.5.1454. [DOI] [PubMed] [Google Scholar]
  126. Ward A. W. Terminal care in malignant disease. Soc Sci Med. 1974 Jul;8(7):413–420. doi: 10.1016/0037-7856(74)90127-9. [DOI] [PubMed] [Google Scholar]
  127. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992 Jun;10(6):890–895. doi: 10.1200/JCO.1992.10.6.890. [DOI] [PubMed] [Google Scholar]
  128. Warner K. E. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics. 1997 Jun;11(6):538–549. doi: 10.2165/00019053-199711060-00003. [DOI] [PubMed] [Google Scholar]
  129. Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer. 1975 Sep;36(3):914–925. doi: 10.1002/1097-0142(197509)36:3<914::aid-cncr2820360312>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  130. Wilcock A., Corcoran R., Tattersfield A. E. Safety and efficacy of nebulized lignocaine in patients with cancer and breathlessness. Palliat Med. 1994;8(1):35–38. doi: 10.1177/026921639400800106. [DOI] [PubMed] [Google Scholar]
  131. Wilkes E. Dying now. Lancet. 1984 Apr 28;1(8383):950–952. doi: 10.1016/s0140-6736(84)92400-0. [DOI] [PubMed] [Google Scholar]
  132. Wolf M., Havemann K., Holle R., Gropp C., Drings P., Hans K., Schroeder M., Heim M., Dommes M., Mende S. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J Clin Oncol. 1987 Dec;5(12):1880–1889. doi: 10.1200/JCO.1987.5.12.1880. [DOI] [PubMed] [Google Scholar]
  133. Yap B. S., Benjamin R. S., Burgess M. A., Murphy W. K., Sinkovics J. G., Bodey G. P. A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults. Cancer. 1981 Jun 15;47(12):2807–2809. doi: 10.1002/1097-0142(19810615)47:12<2807::aid-cncr2820471209>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  134. Zech D. F., Grond S., Lynch J., Hertel D., Lehmann K. A. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995 Oct;63(1):65–76. doi: 10.1016/0304-3959(95)00017-M. [DOI] [PubMed] [Google Scholar]
  135. Ziegler R. G., Mayne S. T., Swanson C. A. Nutrition and lung cancer. Cancer Causes Control. 1996 Jan;7(1):157–177. doi: 10.1007/BF00115646. [DOI] [PubMed] [Google Scholar]

Articles from Quality in Health Care : QHC are provided here courtesy of BMJ Publishing Group

RESOURCES